About CD320 antigen
CD320 antigen (CD320) is a protein
from Homo sapiens identified by UniProt accession
Q9NPF0, 282 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | CD320 antigen |
|---|
| UniProt accession | Q9NPF0 |
|---|
| Gene | CD320 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 282 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (60)
Diseases linked to this target (Open Targets).
- Methylmalonic aciduria due to transcobalamin receptor defect · score 0.48
- methylmalonic acidemia due to transcobalamin receptor defect · score 0.48
- Vitamin B12-responsive methylmalonic acidemia type cblB · score 0.37
- acute myeloid leukemia · score 0.22
- neoplasm · score 0.08
- age-related macular degeneration · score 0.08
- X-linked retinal dysplasia · score 0.06
- severe early-childhood-onset retinal dystrophy · score 0.05
- age related macular degeneration 4 · score 0.05
- age related macular degeneration 7 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NPF0-F1 | alphafold | PREDICTED | 63.82 | — |
Amino-acid sequence (282 residues)
MSGGWMAQVG AWRTGALGLA LLLLLGLGLG LEAAASPLST PTSAQAAGPS SGSCPPTKFQ CRTSGLCVPL TWRCDRDLDC SDGSDEEECR IEPCTQKGQC PPPPGLPCPC TGVSDCSGGT DKKLRNCSRL ACLAGELRCT LSDDCIPLTW RCDGHPDCPD SSDELGCGTN EILPEGDATT MGPPVTLESV TSLRNATTMG PPVTLESVPS VGNATSSSAG DQSGSPTAYG VIAAAAVLSA SLVTATLLLL SWLRAQERLR PLGLLVAMKE SLLLSEQKTS LP
Explore CD320 antigen with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets